Скачать с ютуб Idecabtagene Vicleucel for High-Risk Early Relapse Multiple Myeloma - KarMMa-2 Study в хорошем качестве

Idecabtagene Vicleucel for High-Risk Early Relapse Multiple Myeloma - KarMMa-2 Study

Idecabtagene Vicleucel (ide-cel) in Patients (Pts) with Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Frontline (1L) Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2b Summary: KarMMa-2 is a multicohort, phase 2, multicenter trial evaluating the effectiveness and safety of ide-cel, a CAR T cell therapy, in patients with clinical high-risk early relapse multiple myeloma (MM) who did not undergo frontline autologous stem cell transplantation (ASCT). The results showed that ide-cel infusion led to deep and durable responses, with a high overall response rate of 94% and a complete response rate of 71%. Minimal residual disease negativity was achieved in patients with partial response and complete response. The duration of response, progression-free survival, and overall survival rates were favorable. Grade 3/4 adverse events, such as neutropenia and thrombocytopenia, were common but manageable. Cytokine release syndrome occurred in a majority of patients but was not severe. CAR+ T cell expansion was observed, particularly in patients with a complete response. Patient-reported outcomes demonstrated sustained improvement in quality of life. These findings suggest that ide-cel infusion has a favorable benefit-risk profile and holds promise as a novel treatment option for patients with clinical high-risk early relapse MM without frontline ASCT. Key Points: 1. CAR T cell therapy ide-cel demonstrated deep, durable responses in patients with relapsed and refractory multiple myeloma (RRMM). 2. KarMMa-2 is a multicohort, phase 2, multicenter trial evaluating ide-cel in RRMM and clinical high-risk MM. 3. KarMMa-2 cohort 2b specifically focuses on patients with clinical high-risk early relapse MM who did not undergo frontline autologous stem cell transplantation (ASCT). 4. The primary endpoint of the study was the complete response rate, and secondary endpoints included overall response rate, duration of response, progression-free survival, overall survival, safety, pharmacokinetics, and health-related quality of life. 5. Of the enrolled patients, 89% received ide-cel infusion. 6. The overall response rate was 94%, with a complete response rate of 71%. 7. High rates of minimal residual disease negativity were achieved in patients with partial response and complete response. 8. The duration of response was not reached, and the progression-free survival and overall survival rates were favorable. 9. Grade 3/4 adverse events occurred in 94% of patients, with neutropenia and thrombocytopenia being the most common. 10. Cytokine release syndrome occurred in 84% of patients, but none were grade ≥3. 11. CAR+ T cell expansion was observed, with higher expansion in patients with complete response. 12. Patient-reported outcomes showed sustained improvement in quality of life. 13. The study concluded that ide-cel infusion had a favorable benefit-risk profile in patients with clinical high-risk early relapse MM without frontline ASCT. Authors: Xavier Leleu, Alfred Chung, Noopur Raje, Meera Mohan, Reuben Benjamin, Adam Sperling, Larry D. Anderson, Madhav Dhodapkar, Shambavi Richard, Violetta Kivovich, Sarah Johnston, Fan Wu, Debashree Basudhar, Ethan Thompson, Devender Dhanda, Laurie Eliason, Sinhan Tran, Maria Chaudhry, Melissa Alsina EHA Abstract# S208 _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52... Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.